Sage Therapeutics: SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the Firm

PHILADELPHIA, April 10, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Sage Therapeutics, Inc. (NASDAQ:SAGE) ("Sage") on behalf of the company's long-term investors.Click here for additional information: https://kaskelalaw.com/case/sage-therapeutics/Recently a securities fraud complaint was filed against Sage on behalf of certain investors who purchased or acquired shares of the company's stock between April 12, 2021 and July 23, 2024 (the "Class Period").According to the complaint, during the Class Period, Sage and certain of the company's senior executive officers concealed adverse information and substantial risks associated with Sage's development of three pharmaceuticals: (i) zuranolone (SAGE-217/BIIB125), a flagship drug, then under development in collaboration with affiliates of Biogen Inc. (together, "Biogen"), whose most lucrative potential application was to treat major depressive disorder ("MDD"); (ii) SAGE-718 (dalzanemdor), for the treatment of certain cognitive disorders and diseases; and (iii) SAGE-324 (BIIB124), under development ...Full story available on Benzinga.com